Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 May;27(5):832–835. doi: 10.1128/aac.27.5.832

Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.

K Richardson, K W Brammer, M S Marriott, P F Troke
PMCID: PMC180161  PMID: 2990328

Abstract

The therapeutic potential of UK-49,858, a difluorophenyl bis-triazole derivative, has been assessed by evaluating its activity against systemic infections with Candida albicans in normal mice and rats and in mice with impaired defence mechanisms, against vaginal infections with C. albicans in mice, and against dermal infections with Trichophyton mentagrophytes in guinea pigs. Orally administered ketoconazole was used as a comparative agent throughout, and parenterally administered amphotericin B was included in the study of C. albicans systemic infection in normal mice. The activity of UK-49,858 given orally to mice or rats infected systemically with C. albicans was far superior to that of ketoconazole. In addition, UK-49,858 showed activity comparable to that of amphotericin B when given parenterally, although the latter gave more prolonged protection. UK-49,858 was also effective orally in curing experimental candidal vaginitis in mice and trichophytosis in guinea pigs, against which it was approximately 10 times more active than ketoconazole. These data suggest that UK-49,858 may be of value in the treatment of both C. albicans and dermatophyte fungal infections in man.

Full text

PDF
832

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bistoni F., Baccarini M., Blasi E., Marconi P., Puccetti P., Garaci E. Correlation between in vivo and in vitro studies of modulation of resistance to experimental Candida albicans infection by cyclophosphamide in mice. Infect Immun. 1983 Apr;40(1):46–55. doi: 10.1128/iai.40.1.46-55.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Jevons S., Gymer G. E., Brammer K. W., Cox D. A., Leeming M. R. Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative. Antimicrob Agents Chemother. 1979 Apr;15(4):597–602. doi: 10.1128/aac.15.4.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Marriott M. S., Baird J. R., Brammer K. W., Faulkner J. K., Halliwell G., Jevons S., Tarbit M. H. Tioconazole, a new imidazole-antifungal agent for the treatment of dermatomycoses. Antifungal and pharmacologic properties. Dermatologica. 1983;166 (Suppl 1):1–7. [PubMed] [Google Scholar]
  4. Petranyi G., Georgopoulos A., Mieth H. In vivo antimycotic activity of naftifine. Antimicrob Agents Chemother. 1981 Mar;19(3):390–392. doi: 10.1128/aac.19.3.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ringel S. M. In vitro and in vivo studies of ambruticin (W7783): new class of antifungal antibiotics. Antimicrob Agents Chemother. 1978 May;13(5):762–769. doi: 10.1128/aac.13.5.762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ryley J. F., Wilson R. G., Barrett-Bee K. J. Azole resistance in Candida albicans. Sabouraudia. 1984;22(1):53–63. [PubMed] [Google Scholar]
  7. Sobel J. D., Muller G. Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis. Antimicrob Agents Chemother. 1984 Aug;26(2):266–267. doi: 10.1128/aac.26.2.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Spanel-Borowski K., Wildfeuer A., Meister H., Haferkamp O. Experimentelle Candida-Vaginitis der Maus. Arch Gynakol. 1976 Dec 10;221(4):313–322. doi: 10.1007/BF00667025. [DOI] [PubMed] [Google Scholar]
  9. Stamm A. M., Dismukes W. E. Current therapy of pulmonary and disseminated fungal diseases. Chest. 1983 Jun;83(6):911–917. doi: 10.1378/chest.83.6.911. [DOI] [PubMed] [Google Scholar]
  10. Thienpont D., Van Cutsem J., Borgers M. Ketoconazole in experimental candidosis. Rev Infect Dis. 1980 Jul-Aug;2(4):570–577. doi: 10.1093/clinids/2.4.570. [DOI] [PubMed] [Google Scholar]
  11. Thienpont D., Van Cutsem J., Van Gerven F., Heeres J., Janssen P. A. Ketoconazole -- a new broad spectrum orally active antimycotic. Experientia. 1979 May 15;35(5):606–607. doi: 10.1007/BF01960348. [DOI] [PubMed] [Google Scholar]
  12. Wildfeuer A. Die Chemotherapie der vaginalen Trichomoniasis und Candidosis der Maus. Arzneimittelforschung. 1974 Jun;24(6):937–943. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES